Pfizer, the largest pharmaceutical company in the United States, has sold its remaining 7.3% stake in the London-listed consumer healthcare company Haleon for a net price of £2.5 billion (approximately $3.25 billion). The sale involved 618 million shares of Haleon stock at a price of 385 pence per share, representing a 1.55% discount to Haleon's closing price of 391.10 pence.
In addition to the sale, Haleon repurchased 44 million shares from Pfizer at the same price. Haleon, known for brands such as Sensodyne toothpaste, Aquafresh mouthwash, and over-the-counter medicines like Panadol and Advil, was formed in July 2019 through the merger of GlaxoSmithKline's and Pfizer's consumer healthcare businesses. The company was later spun off and listed on the London Stock Exchange in July 2022.
GSK sold its remaining shares in Haleon on May 16, 2024.
